Curanex Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Nasdaq Minimum Bid Price Compliance Deadline | 2 Nov 2026 |
| Planned Phyto-N IND Submission to the FDA | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly4MTarget: Sufficient capital to support near-term IND-enabling activities
Phyto-N IND Submission Progress QuarterlyTarget: FDA submission for ulcerative colitis in Q4 2026
Nasdaq Minimum Bid Price Compliance Daily0.3Target: At or above $1.00 per share for at least 10 consecutive business days
Watch Items
- Nasdaq Delisting RiskTrigger: Failure to maintain a minimum bid price of $1.00 by November 2, 2026Action: Implement a reverse stock split at an approved ratio between 1-for-10 and 1-for-50 to artificially boost the share price.
- Wolf Haldenstein Securities Fraud InvestigationTrigger: Filing of formal class action lawsuits or regulatory enforcement actionsAction: Monitor legal developments, cooperate with investigations, and assess potential financial and reputational liabilities.
- GLP Toxicology and Pharmacokinetic Studies for Phyto-NTrigger: Any treatment-related adverse findings of toxicological significanceAction: Re-evaluate dose levels, adjust IND-enabling study designs, and update the FDA regulatory strategy.
Research as of 20 Jun 2026